The U.S. Food and Drug Administration (FDA) has just approved Xyzal®, a new once-daily prescription antihistamine that delivers a rapid and long-lasting effect for the relief of symptoms associated with seasonal and year round allergies and chronic hives in adults and children six years of age and older.
Estimates from the American College of Allergy, Asthma and Immunology suggest that allergies affect as many as 40 to 50 million people in the United States. As modern living has become more complex, so have allergies with the disease and subsequent allergy seasons becoming longer and more severe. Among others, outdoor pollution, indoor air quality problems, and exposure to airborne and food allergens are all playing a role in the surge in allergies.
Xyzal® once-daily tablets are expected to be available during the 2007 fall allergy season.
For more information as well as full prescribing information, visit http://www.ucb-group.com/products/allergy_respiratory_pc/xyzal/ or http://products.sanofi-aventis.us/xyzal/xyzal.pdf.